Premature Ejaculation (PE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Premature Ejaculation (PE) Market Outlook

Thelansis’s “Premature Ejaculation (PE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Premature Ejaculation treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Premature Ejaculation (PE) Overview

In the male reproductive system, ejaculation refers to the release and external expression of semen. Premature ejaculation is a term used to describe the occurrence of ejaculation happening consistently earlier than desired by a man or his partner during sexual activity. This condition is recognized as the most prevalent male sexual disorder. Primarily of psychological origin, premature ejaculation's precise cause remains largely unknown. Various contributing risk factors have been identified, encompassing biological and psychological aspects. Biological factors include abnormal levels of the brain neurotransmitter serotonin, abnormal hormonal levels, hypogonadism, inflammation or infection of the prostate or urethra, and erectile dysfunction. Psychological factors include depression, anxiety, stress, guilt, narcissism, distorted thinking, unrealistic expectations about sexual performance, performance anxiety, history of sexual repression, overall lack of confidence or poor body image, and history of sexual abuse or prior negative experiences. The control of ejaculation is regulated by the spinal ejaculatory generator center, located at the L1-L2 level. This center receives inputs from the penile nerves, both parasympathetic and sympathetic, and communicates through sensory and motor nerves. Alongside the spinal ejaculatory center, the central, spinal, and peripheral nervous systems collaboratively function for emission and ejaculation. A normal ejaculation is a complex but well-coordinated sequence of physiological events involving three phases: emission, expulsion, and orgasm. Before diagnosing premature ejaculation, other conditions must be considered, such as severely delayed orgasm in the female partner. The average time to reach climax in females is 12 to 25 minutes. In cases of extremely delayed female orgasm, almost any male would be perceived as experiencing premature ejaculation, making the partner's sexual response a factor that necessitates evaluation. Common treatment options for premature ejaculation include behavioral techniques, medications, and counseling. Topical applications such as creams, gels, or sprays containing numbing agents like benzocaine, lidocaine, or prilocaine are used to alleviate premature ejaculation. These substances are applied to the penis 10 to 15 minutes before sexual activity to reduce sensation and delay ejaculation.

• Premature ejaculation (PE) is the most common sexual disorder among men, affecting an estimated 30% to 50% of the male population worldwide.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: